Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | NTRK2 | Q16620 | 1/20 | 1.00 |
| ▸ | GSK3B | P49841 | 5/20 | 0.76 |
| ▸ | AURKA | O14965 | 4/20 | 0.56 |
| ▸ | SYK | P43405 | 2/20 | 0.56 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.56 |
| ▸ | IGF1R | P08069 | 3/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | GSK3A | P49840 | 4/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 2/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6674805 | 0.99 | CHEK1 (0.98) | CHEK1NTRK2GSK3BAURKASYK | |
| SCHEMBL5262378 | 0.86 | GSK3B (1.00) | CHEK1NTRK2GSK3BAURKASYK | |
| SCHEMBL5263616 | 0.86 | CHEK1 (0.76) | CHEK1NTRK2GSK3BAURKAPTK2 | |
| SCHEMBL5263108 | 0.86 | AURKA (0.79) | CHEK1NTRK2GSK3BAURKASYK | |
| SCHEMBL5262926 | 0.84 | GSK3B (0.81) | CHEK1NTRK2GSK3BAURKAPTK2 | |
| SCHEMBL27914835 | 0.81 | CHEK1 (0.67) | CHEK1NTRK2AURKASYKPTK2 | |
| SCHEMBL3634270 | 0.79 | HDAC3 (0.74) | CHEK1NTRK2AURKASYKPTK2 | |
| Hydrochloric Acid SCHEMBL6676130 | 0.79 | GSK3B (0.72) | CHEK1NTRK2GSK3BAURKASYK | |
| SCHEMBL1735277 | 0.79 | CSNK2A1 (0.68) | CHEK1NTRK2HDAC3HDAC1HDAC2 | |
| SCHEMBL5262136 | 0.78 | GSK3B (0.78) | CHEK1NTRK2GSK3BAURKAPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268444-B1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-17 | — | — | EP | disclosed |
| CN-1211373-C | 2,4-di (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2005-07-20 | — | — | CN | disclosed |
| WO-2004039359-A2 | USE OF PYRIMIDINE DERIVATES FOR THE MANIFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-05-13 | — | — | WO | disclosed |
| US-6649608-B2 | Cyclin-dependent serine/threonine and focal adhesion kinase inhibitors | ASTRAZENECA AB (SE) | 2003-11-18 | — | — | US | disclosed |
| US-20030149266-A1 | 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | disclosed |
| CN-1406230-A | 2,4-di (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-03-26 | — | — | CN | disclosed |
| EP-1268444-A1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS | AstraZeneca AB (SE) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001064655-A1 | 2, 4-DI(HETERO-)ARYLAMINO (-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149266-A1 | 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents | CDK2, CCNI, CDK1 | CHEK1 62/4885NTRK2 2841/4885GSK3B 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.